Flohé L
Grünenthal GmbH, Center of Research, Aachen, FRG.
Mol Cell Biochem. 1988 Dec;84(2):123-31. doi: 10.1007/BF00421046.
The clinical trials performed with bovine superoxide dismutase (SOD) are reviewed. SOD, applied intraarticularly at a dosage of 2-16 mg, proved to be effective in osteoarthritis of the knee joint in three placebo-controlled and one steroid-controlled double-blind trials. Its efficacy in other inflammatory joint disorders is documented by uncontrolled trials. Similarly, some controlled and many open studies support the efficacy of locally injected SOD in periarticular inflammation. Systemic treatment of rheumatoid arthritis by SOD at the dosages indicated yielded disappointing results. Well documented, though open uncontrolled studies demonstrated beneficial effects of locally administered SOD in radiation cystitis, interstitial cystitis and Peyronie's disease. Tolerance is good, but allergic reactions at low incidence have to be anticipated. Human SOD derived from recombinant microorganisms is being developed to explore its therapeutic potential particularly in ischemia-reperfusion damage, adult respiratory distress or similar conditions.
本文回顾了使用牛超氧化物歧化酶（SOD）进行的临床试验。在三项安慰剂对照和一项类固醇对照的双盲试验中，以2 - 16毫克的剂量关节内应用SOD，被证明对膝关节骨关节炎有效。其在其他炎症性关节疾病中的疗效有非对照试验记录。同样，一些对照研究和许多开放研究支持局部注射SOD对关节周围炎症的疗效。以所示剂量用SOD对类风湿性关节炎进行全身治疗产生了令人失望的结果。虽然是开放的非对照研究，但有充分记录表明局部应用SOD对放射性膀胱炎、间质性膀胱炎和佩罗尼氏病有有益作用。耐受性良好，但必须预期会有低发生率的过敏反应。源自重组微生物的人SOD正在研发中，以探索其治疗潜力，特别是在缺血再灌注损伤、成人呼吸窘迫或类似病症中的潜力。
